Following on in same article there is a video link:
In the exclusive interview, Dr. Muchnicki discusses the Company’s cancer predictive testing and assessment tools to help physicians proactively manage patient health. Also discussed is the global market opportunity, upcoming predictive testing milestones and the capacity for Covid-19 (SDR) serious disease risk testing and the company’s developing pipeline of risk assessment products including guideline driven reimbursable Germline panel testing for cancers, heart disease and metabolic diseases such as Type 2 Diabetes.
